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Carrier Screening for Mucolipidosis Type IV in the American Ashkenazi
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Department of Human Genetics, Mount Sinai School of Medicine, New York University, New York
Mutations in the MCOLN1 gene cause mucolipidosis type IV (MLIV), a severely debilitating, autosomal recessive,
lysosomal storage disorder. Approximately 80% of patients with MLIV are of Ashkenazi Jewish (AJ) descent, and
two mutations, IVS352ArG and 511del6434, account for 195% of the mutant alleles in this population. To
determine the carrier frequencies of these two mutations, 2,029 anonymous, unrelated, unaffected AJ individuals
from the greater New York metropolitan area were screened. A multiplex PCR method coupled with allele-specific
oligonucleotide hybridization was developed, to enable large-scale screening. The frequencies of the IVS352ArG
and 511del6434 mutations were 0.54% and 0.25%, respectively, for a combined carrier frequency of 0.79%, or
1 in 127 individuals (95% CI 0.40%–1.17%). The addition of both AJ mutations causing this neurodegenerative
disorder should be considered for prenatal carrier screening in this population.
Mucolipidosis type IV (MLIV [MIM 252650]) is a neu-
rodegenerative lysosomal storage disorder that is inher-
ited as an autosomal recessive trait. Clinically, the dis-
ease, which occurs primarily among Ashkenazi Jewish
(AJ) individuals, is characterized by growth and psy-
chomotor retardation, as well as ophthalmologic ab-
normalities, which include corneal clouding, progressive
retinal degeneration, and strabismus (Berman et al.
1974; Riedel et al. 1985). There is clinical variability,
but most patients never develop the ability to speak or
walk and remain at a developmental level of age 1–2
years. Although the disorder is associated with the ac-
cumulation of cytoplasmic storage bodies, normal levels
of lysosomal hydrolases are present, with no specific
identifiable storage compound (Amir et al. 1987). Elec-
tron photomicrographs of tissue biopsies from patients
with MLIV have shown a widespread heterogeneous ac-
cretion of lipids and water-soluble compounds, indicat-
ing that the etiology of the disease is probably not related
to the deficiency of a particular lysosomal enzyme but
rather to a defect in endocytosis (Bargal and Bach 1997;
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Chen et al. 1998). It has been suggested that many cases
may not be properly diagnosed, because of the varia-
bility in the observed phenotype and the lack of an in-
dicative storage compound.
The MLIV locus was mapped to chromosome 19p13
in AJ families, and haplotype analysis of these families
indicated that there were two founder chromosomes that
accounted for 73% (major haplotype) and 23% (minor
haplotype)—a total of 96%—of the carrier chromo-
somes in the AJ population (Slaugenhaupt et al. 1999;
Sun et al. 2000). Recently, the gene that is mutated in
patients with MLIV,MCOLN1 (MIM 605248), was iso-
lated, and the two AJ founder mutations were identi-
fied. These mutations were (1) a splicing mutation,
IVS32ArG, which resulted in skipping of exon 4,
with the subsequent loss of the reading frame, and
(2) a 6,434-bp deletion spanning genomic nucleotides
511–6,944, designated “511del6434,” which included
the 5′ flanking region of the gene through exon 7 (Bargal
et al. 2000; Bassi et al. 2000; Sun et al. 2000). Since
both mutations resulted in the loss of a functional gene
product, the severity of the phenotype was similar in
patients who were homoallelic or heteroallelic for these
mutations.
The MCOLN1 gene encodes the putative protein mu-
colipin-1, which is 580 amino acids long and is some-
what homologous to the polycystins, a family of cation
channels (Somlo and Ehrlich 2001). In Caenorhibditis
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Figure 1 Multiplex PCR of the MCOLN1 gene; 2% agarose gel
showing the products that result from the multiplex PCR amplification
of the MCOLN1 gene with the IVS32ArG and 511del6434 primer
pairs. Note that the 511del6434 primers amplify a product only when
the deletion is present.
elegans, studies of cup-5, the mucolipin-1 homolog, have
indicated that these proteins are vesicle membrane–
associated regulators of the endocytic pathway, where
loss of cup-5 function results in large lysosomal or late
endosomal structures that exhibit both an increase in
the rate of uptake of fluid phase markers and a decrease
in the ability to degrade proteins (Fares and Greenwald
2001). The function of mucolipin-1 that is predicted on
the basis of these studies is consistent with the lysosomal
pathology observed in cultured cells derived from pa-
tients with MLIV.
To determine the frequency of carriers for MLIV in
the AJ population, we screened for both the major
IVS32ArG and the minor 511del6434 mutations in
genomic DNAs isolated from blood samples obtained
from 2,029 unrelated AJ individuals from the New York
metropolitan area who were referred for prenatal carrier
testing for other genetic disorders prevalent in the AJ pop-
ulation. DNA was extracted from peripheral blood ob-
tained by venipuncture and archived with informed con-
sent for use in research studies. All personal identifiers
were removed, and the samples were tested anonymously.
A multiplex PCR amplification was performed for 28 cy-
cles with 100 ng of genomic DNA in a volume of 50 ml
containing 10 pmol of each primer tagged with a 5′ uni-
versal primer sequence (UPS) (Shuber et al. 1995). The




CTCGTCCTG-3′), and the primer sequences designed to
detect the minor mutation were MLIV-3UPS (5′-GCGG-
TCCCAAAAGGGTCAGTGGCAGCTTTCTCAATGA-
AGG-3′ and MLIV-4UPS (5′-GCGGTCCCAAAAGGGT-
CAGTTCACCGTGCTGGAAGACACT-3′). In addition,
100 mM of each dNTP (Roche Molecular Biochemicals),
5 U of Taq DNA polymerase (Roche), 10 mM Tris-HCl,
50 mM KCl, 0.1% TritonX-100, and 1.5 mM MgCl2
were added to the PCRs. Dimethyl sulfoxide (Sigma) was
added to a final concentration of 4%, because of the high
(65%) GC content of the region amplified for analysis of
the major mutation. The primers were designed from the
genomic sequence of the MCOLN1 gene (Sun et al. 2000;
GenBank accession number AF287270) to amplify a 410-
bp PCR product encompassing the IVS32ArG muta-
tion and a 396-bp PCR product when a 511del6434 mu-
tation was present (fig. 1). Therefore, the multiplex PCR
amplification of DNA from individuals with neither mu-
tation and individuals who were heterozygous or ho-
mozygous for the IVS32ArG mutation would result in
a single PCR product of 410 bp (fig. 1). Amplification
of DNA from individuals who were carriers of the
511del6434 mutation or heteroallelic for both mutations
would result in PCR products of 396 bp and 410 bp,
respectively, whereas amplification of DNA from individ-
uals who were homozygous for the 511del6434 mutation
would result only in products of 396 bp (fig. 1). Control
DNAs were obtained from the fibroblast cell lines
GM02527, GM02529, and GM02525 (Coriell NIGMS
Human Genetic Cell Repository), which were derived
from patients with MLIV who were homozygous for the
IVS32ArG mutation, compound heterozygous for the
IVS32ArG/511del6434 mutations, and homozygous
for the 511del6434 mutation, respectively (Bassi et al.
2000).
Aliquots (4 ml) of the PCR products were blotted in
triplicate onto 8#12 cm Hybond N membranes
(Amersham Pharmacia Biotech) through use of a Biomek
2000 automated pipetting workstation (Beckman Coul-
ter). Hybridization was performed with the following al-
lele-specific oligonucleotides (ASOs): for the IVS32ArG
mutation, 5′-TCTCTGCCCACAGTACCTG-3′ (normal)
and 5′-TCTCTGCCCACGGTACCTG-3′ (mutant); and
for the 511del6434 mutation, 5′-CCTGGGCTCAACAA-
AGCAC-3′. For radioactive detection, the membranes
were hybridized, for a length of time ranging from 2 h
to overnight, with ∼106 counts per minute of g-[32P]ATP
end-labeled probe/ml and 10-fold molar excess of the
mutant or wild-type competitor oligonucleotide for
the IVS32ArG mutation. The membranes were then
washed sequentially in 5# saline sodium citrate (SSC) for
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Figure 2 ASOs of the two AJ MCOLN1 mutations. Shown are
autoradiographs of dot blots hybridized with the normal IVS32ArG
ASO (left), the mutant IVS32ArG ASO (middle), and the
511del6434 ASO (right). PCR samples 1–95 were amplified from ge-
nomic DNAs; sample 96 is the ddH2O control. Sample 1 was amplified
from the IVS32ArG homozygote (GM02527), sample 8 was am-
plified from the 511del6434 homozygote (GM02525), samples 18 and
67 were amplified from carriers of the IVS32ArG mutation, and
sample 49 was amplified from a carrier of the 511del6434 mutation.
Table 1





















Bargal et al. 2001 (Israel) 2,000 17 .85 (1/117) 1 .05 (1/2,000) 19a .95 (1/106)b
Wang et al. 2001 (New York) 123 2 1.62 (1/62) 0 0 2 1.62 (1/62)
Present study (New York) 2,029 11 .54 (1/184) 5 .25 (1/406) 16 .79 (1/127)c
Combined 4,152 30 .72 (1/138) 6 .14 (1/692) 37 .89 (1/112)
a This number is based on an estimate of a 95% detection rate of MLIV carriers.
b 95% CI p .52%–1.39%.
c 95% CI p .40%–1.17%.
5 min at room temperature and in 5#SSC for 5 min at
45C, followed by a wash in 0.1#SSC/0.1% SDS for 5
min at 45C. Filters were then exposed to autoradiog-
raphy by use of Biomax MR film (Kodak) (fig. 2).
For the major IVS32ArG mutation, 2,029 AJ in-
dividuals were screened and 11 carriers were identified,
corresponding to a frequency of 0.54%, or 1/184. Five
carriers for the minor 511del6434 mutation were iden-
tified in a total of 2,029 AJ individuals tested, corre-
sponding to a frequency of 0.25%, or 1/406. The com-
bined frequency of the two mutations in the present
study was, therefore, 0.79%, or 1/127 individuals (95%
CI 0.40%–1.17%) (table 1). Because the haplotypes that
correspond to these two mutations account for 96% of
the carriers in the AJ population, the prevalences of the
two mutations were 66% and 30% for the major and
minor mutations, respectively. These percentages are in
agreement with the results of Sun and colleagues (2000),
who reported that the major and minor haplotypes are
present on 73% and 23% of carrier chromosomes,
respectively.
In a recent report (Wang et al. 2001), a small study
of 123 AJ individuals was conducted, and a carrier fre-
quency of 1/61 was reported for the major IVS32ArG
mutation; however, no carriers for the minor
511del6434 mutation were identified (table 1). There-
fore, the limited sample size prevented a reliable estimate
of the frequency and distribution of MLIV carriers. Re-
cently, Bargal et al. (2001) reported a carrier frequency
of 1/100 for the two mutations in a sample of 2,000 AJ
individuals from Israel (table 1). The distribution of the
mutations was 94% for the major mutation and 6% for
the minor mutation. This apparent disparity in the fre-
quency of carriers between the AJ constituencies of the
New York metropolitan area and Israel is not clear; how-
ever, the major mutation is more prevalent in the Israeli
population and probably accounts for the observed
higher frequency of total carriers of MLIV. These find-
ings also may be indicative of different patterns of im-
migration of AJ individuals into the United States and
Israel and/or may reflect distinct regional origins of the
founders of the major and the minor mutation.
In a study of 17 Israeli AJ families with MLIV, familial
origins were traced back to Poland or to neighboring
Lithuania (Raas-Rothschild et al. 1999). The authors
speculated that the underrepresentation of ultra-ortho-
dox families among the 80 AJ families with MLIV
worldwide might indicate a recent origin for the mu-
tation, around the 18th and 19th centuries, in a founder
that belonged to a secular family. These findings are
likely to be specific for the major mutation, on the basis
of its higher prevalence (94%) among the Israeli AJ pop-
ulation. Discordant carrier rates between Israeli and
American Ashkenazi subpopulations have been reported
recently for mutations in the Connexin 26 gene, which
cause nonsyndromic sensorineural recessive deafness
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(Dong et al. 2001). Variation in the frequency of MLIV
carriers between the United States and Israel thus pro-
vides further evidence that Ashkenazi subpopulations
have not reached equilibrium.
A more recent origin for the two AJ MLIV founder
mutations would explain why the frequency of carriers
for MLIV is not as high as the frequencies of other mu-
tations that are common in the AJ population, including
some that originated in or were introduced into the Eu-
ropean Jewish population 11,000 years ago (Diaz et al.
2000). The carrier frequencies of these disorders range
from 1/18, for Gaucher disease (Beutler and Grabowski
2000), to 1/107, for Bloom syndrome (Li et al. 1998).
The observed frequency of MLIV carriers within a large
cohort of AJ individuals from the New York metropol-
itan area is 1/127, slightly lower than the frequency of
disorders for which carrier screening is currently avail-
able. However, in light of the neurologic severity of the
MLIV phenotype, for which there is no available treat-
ment, and the fact that the two mutations account for
195% of carriers, carrier screening for the two mutations
should be considered for this population.
Acknowledgments
The authors would like thank all the individuals who agreed
to participate anonymously in this study. We also thank Asghar
Bajwa and Jing Xu for their technical assistance. This work
was supported, in part, by grants from the National Institutes
of Health, including a Merit Award (grant 5 R37 DK34045),
grant 5 M01 RR00071 to the Mount Sinai General Clinical
Research Center, and grant 5 P30 HD28822 to the Mount
Sinai Child Health Research Center.
Electronic-Database Information
Accession numbers and URLs for data in this article are as
follows:
Genbank, http://www.ncbi.nlm.nih.gov/Genbank/ (for Homo
sapiens MCOLN1, complete coding sequence [accession
number AF287270])
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for MLIV [MIM 252650] and
mucolipin-1 [MIM 605248])
References
Amir N, Zlotogora J, Bach G (1987) Mucolipidosis type IV:
clinical spectrum and natural history. Pediatrics 79:953–
959
Bargal R, Avidan N, Ben-Asher E, Olender Z, Zeigler M, Frum-
kin A, Raas-Rothschild A, Glusman G, Lancet D, Bach G
(2000) Identification of the gene causing mucolipidosis type
IV. Nat Genet 26:118–123
Bargal R, Avidan N, Olender T, Ben Asher E, Zeigler M, Raas-
Rothschild A, Frumkin A, Ben-Yoseph O, Friedlender Y,
Lancet D, Bach G (2001) Mucolipidosis type IV: novel
MCOLN1 mutations in Jewish and non-Jewish patients and
the frequency of the disease in the Ashkenazi Jewish pop-
ulation. Hum Mutat 17:397–402
Bargal R, Bach G (1997) Mucolipidosis type IV: abnormal
transport of lipids to lysosomes. J Inherit Metab Dis 20:
625–632
Bassi MT, Manzoni M, Monti E, Pizzo MT, Ballabio A, Borsani
G (2000) Cloning of the gene encoding a novel integral
membrane protein, mucolipin-1, and identification of the
two founder mutations causing mucolipidosis type IV. Am
J Hum Genet 67:1110–1120
Berman ER, Livni N, Shapira E, Merin S, Levij IS (1974) Con-
genital corneal clouding with abnormal systemic storage
bodies: a new variant of mucolipidosis. J Pediatr 84:519–
526
Beutler E, Grabowski GA (2000) Gaucher’s disease. In: Beau-
det A, Childs B, Kinzler K, Scriver CR, Sly WS, Valle D,
Vogelstein B (eds) The metabolic and molecular bases of
inherited disease, 8th ed. McGraw-Hill, New York, pp
3635–3668
Chen CS, Bach G, Pagano R E (1998) Abnormal transport
along the lysosomal pathway in mucolipidosis type IV dis-
ease. Proc Nat Acad Sci USA 95:6373–6378
Diaz GA, Gelb BD, Risch N, Nygaard TG, Frisch A, Cohen
IJ, Miranda CS, Amaral O, Maire I, Poenaru L, Caillaud
C, Weizberg M, Mistry P, Desnick RJ (2000) Gaucher dis-
ease: the origins of the Ashkenazi Jewish N370S and 84GG
acid b-glucosidase mutations. Am J Hum Genet 66:1821–
1832
Dong J, Katz DR, Eng CM, Kornreich R, Desnick RJ (2001)
Nonradioactive detection of the common Connexin 26
167delT and 35delG mutations and frequencies among Ash-
kenazi Jews. Mol Genet Metab 73:160–163
Fares H, Greenwald I (2001)Regulation of endocytosis by
CUP-5, the Caenorhabditis elegans mucolipin-1 homolog.
Nat Genet 28:64–68
Li L, Eng C, Desnick RJ, German J, Ellis NA (1998) Carrier
frequency of the Bloom syndrome blmAsh mutation in the
Ashkenazi Jewish population. Mol Genet Metab 64:286–
290
Raas-Rothschild A, Bargal R, DellaPergola S, Zeigler M, Bach
G (1999) Mucolipidosis type IV: the origin of the disease in
the Ashkenazi Jewish population. Eur J Hum Genet 7:
496–498
Riedel KG, Zwaan J, Kenyon KR, Kolodny EH, Hanninen L,
Albert DM (1985) Ocular abnormalities in mucolipidosis
IV. Am J Ophthalmol 99:125–136
Shuber AP, Grondin VJ, Klinger KW (1995) A simplified pro-
cedure for developing multiplex PCRs. Genome Res 5:488–
493
Slaugenhaupt SA, Acierno JS Jr, Helbling LA, Bove C, Goldin
E, Bach G, Schiffmann R, Gusella JF (1999) Mapping of
the mucolipidosis type IV gene to chromosome 19p and
definition of founder haplotypes. Am J Hum Genet 65:
773–778
Reports 1027
Somlo S, Ehrlich B (2001) Human disease: calcium signaling
in polycystic kidney disease. Curr Biol 11:R356–R360
Sun M, Goldin E, Stahl S, Falardeau JL, Kennedy JC, Acierno
JS Jr, Bove C, Kaneski CR, Nagle J, Bromley MC, Colman
M, Schiffmann R, Slaugenhaupt SA (2000) Mucolipidosis
type IV is caused by mutations in a gene encoding a novel
transient receptor potential channel. Hum Mol Genet 9:
2471–2478
Wang ZH, Zeng B, Pastores GM, Raksadawan N, Ong E,
Kolodny EH (2001) Rapid detection of the two common
mutations in Ashkenazi Jewish patients with mucolipidosis
type IV. Genet Test 5:87–92
